Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Hepatitis B (HBV) reactivation and hepatitis flare induced by cytotoxic chemotherapy is
common in cancer patients who have chronic HBV infection. Lymphoma patients who had previous
infected by HBV but negative for HBsAg have a the risk of HBV reactivation during
chemotherapy, but prophylactic antiviral treatment is not a routine by current American
Association for the Study of Liver Diseases (AASLD) guideline. Prophylactic entecavir might
reduce the risk of HBV reactivation in such patients.